S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Intersect ENT Stock Forecast, Price & News

+0.03 (+0.11%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
199,508 shs
Average Volume
383,455 shs
Market Capitalization
$906.15 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Intersect ENT logo

About Intersect ENT

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.


Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
November 18, 2021 |  finance.yahoo.com
Reviewing Endologix (OTCMKTS:ELGXQ) and Intersect ENT (NASDAQ:XENT)
November 16, 2021 |  americanbankingnews.com
Intersect ENT Reports Third Quarter 2021 Financial Results
November 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$80.55 million
Book Value
$0.48 per share


Net Income
$-72.32 million
Pretax Margin




Free Float
Market Cap
$906.15 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.59 out of 5 stars

Medical Sector

1037th out of 1,388 stocks

Surgical & Medical Instruments Industry

106th out of 126 stocks

Analyst Opinion: 1.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

How has Intersect ENT's stock price been impacted by Coronavirus?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XENT shares have increased by 26.0% and is now trading at $27.08.
View which stocks have been most impacted by COVID-19

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Intersect ENT

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.06. Intersect ENT had a negative net margin of 85.02% and a negative trailing twelve-month return on equity of 151.36%.
View Intersect ENT's earnings history

What price target have analysts set for XENT?

5 brokerages have issued 12-month price targets for Intersect ENT's shares. Their forecasts range from $23.00 to $28.30. On average, they expect Intersect ENT's stock price to reach $26.95 in the next year. This suggests that the stock has a possible downside of 0.5%.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Thomas A. West, President, Chief Executive Officer & Director
  • Randy Meier, Chief Financial Officer & Executive Vice President
  • Patrick A. Broderick, Secretary, Executive VP & General Counsel
  • Mark L. Alley, Vice President-Sales
  • Reyna M. Fernandez, Chief Human Resource Officer

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.75%), Magnetar Financial LLC (7.64%), Versor Investments LP (6.76%), Millennium Management LLC (4.71%), Artisan Partners Limited Partnership (4.35%) and Alpine Associates Management Inc. (4.16%). Company insiders that own Intersect ENT stock include Richard A Meier and Thomas A West.
View institutional ownership trends for Intersect ENT

Which institutional investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Polar Asset Management Partners Inc., BlackRock Inc., Neuberger Berman Group LLC, UBS Group AG, Dimensional Fund Advisors LP, Citadel Advisors LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Intersect ENT
or view top insider-selling stocks.

Which institutional investors are buying Intersect ENT stock?

XENT stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Versor Investments LP, Millennium Management LLC, Alpine Associates Management Inc., Morgan Stanley, Alliancebernstein L.P., Omni Partners US LLC, and CNH Partners LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $27.08.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $906.15 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72.32 million in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100, via email at [email protected], or via fax at 866-736-1251.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.